Sylvant (siltuximab)
Sylvant 100 MG Injection
NO BOXED WARNING
Dosage & Administration
For intravenous infusion only.
Administer as an 11 mg/kg dose given over 1 hour by intravenous infusion every 3 weeks. ( 2)
Sylvant Prescribing Information
Sylvant Financial Assistance Options
Copay savings program
Learn More
Overview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Foundation programs
Learn More
Overview
- Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
- These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
- Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted
Patient eligibility
- Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
- Patients submit proof of out-of-pocket drug costs to charities for reimbursement
Sylvant PubMed™ News
Sylvant Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Sylvant FAQs
The limited available information on SYLVANT use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage. However, infants born to pregnant women treated with SYLVANT may be at increased risk of infection. It is advised to inform pregnant women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.
Monoclonal antibodies like SYLVANT are transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Infants born to pregnant women treated with SYLVANT may be at increased risk of infection. It is advised to consider the risks and benefits of administering live or live-attenuated vaccines to infants exposed to SYLVANT in utero.
There are no data on the presence of siltuximab in human milk, the effects on the breastfed child, or the effects on milk production. However, low levels of the human antibody to IL-6 were present in the milk of lactating cynomolgus monkeys. Because of the potential for serious adverse reactions in the breastfed child including gastrointestinal perforations, it is advised to not breastfeed during treatment with SYLVANT and for 3 months after the last dose.
SYLVANT may cause embryo-fetal harm when administered to pregnant women. Female patients of reproductive potential should use effective contraception during treatment with SYLVANT and for 3 months after the last dose.
The safety and efficacy of SYLVANT have not been established in pediatric patients.
No overall differences in safety profile were observed between elderly patients and younger patients in clinical studies. However, clinical studies did not include sufficient numbers of patients aged 65 years and older to determine the effect of age on efficacy in MCD population.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available